OncoLens replaces the current labor intensive process of patient case collaboration and subsequent CoC accreditation in cancer care.
OncoLens has raised $16.0M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
OncoLens's investors include SeedToB Capital, BIP Capital, Cross-Border Impact Ventures, Martin Ventures, Atlanta Technology Angels.
OncoLens is headquartered in Atlanta, United States.
OncoLens replaces the current labor intensive process of patient case collaboration and subsequent CoC accreditation in cancer care.
OncoLens is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoLens — Funding & Investors." VCBacked, October 24, 2024, https://www.vcbacked.co/company/oncolens. Accessed October 29, 2026.
VCBacked. (2024). OncoLens — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/oncolens
{{cite web |title=OncoLens — Funding & Investors |url=https://www.vcbacked.co/company/oncolens |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated